Provided by Tiger Trade Technology Pte. Ltd.

Regenxbio

8.63
-0.1000-1.15%
Volume:153.65K
Turnover:1.32M
Market Cap:569.69M
PE:-2.29
High:8.79
Open:8.63
Low:8.47
Close:8.73
52wk High:16.19
52wk Low:5.46
Shares:66.01M
Float Shares:57.34M
Volume Ratio:1.23
T/O Rate:0.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7652
EPS(LYR):-3.7593
ROE:-137.63%
ROA:-21.20%
PB:7.94
PE(LYR):-2.30

Loading ...

Regenxbio Announces Alignment With FDA on Path Forward for Navsunli™ Bla Resubmission for Accelerated Approval; First Potential Gene Therapy for Mps Ii

THOMSON REUTERS
·
Jun 22

Regenxbio - to Resubmit Navsunli Bla in Q3 2026

THOMSON REUTERS
·
Jun 22

Regenxbio Inc: Expects Type a Meeting to Take Place in July and to Resubmit the Bla Rapidly Following the Meeting in Q3 2026-Spokesperson

THOMSON REUTERS
·
Jun 22

Regenxbio: We Aligned With FDA Regarding Next Steps Needed for Potential Accelerated Approval of Navsunli - Spokerperson

THOMSON REUTERS
·
Jun 22

BUZZ-Regenxbio rises after report FDA to reverse rejection of rare-disease gene therapy

Reuters
·
Jun 22

Regenxbio Shares Up on WSJ Report of FDA U-Turn on Company's Gene Therapy

Dow Jones
·
Jun 22

Regenxbio Shares up 11.2% Premarket After Report US FDA to Reverse Rejection of Co's Rare-Disease Drug

THOMSON REUTERS
·
Jun 22

Regenxbio up 25% after saying FDA will reverse rejection, consider application

TIPRANKS
·
Jun 22

BRIEF-FDA Will Reverse Rejection Of Third Rare-Disease Drug, Regenxbio Says- WSJ

Reuters
·
Jun 22

Regenxbio tells WSJ that FDA will reverse rejection of drug

TIPRANKS
·
Jun 22

Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says

MT Newswires Live
·
Jun 18

REGENXBIO Up Over 23%, on Pace for Largest Percent Increase Since September 2021 -- Data Talk

Dow Jones
·
Jun 18

Analysts Are Bullish on Top Healthcare Stocks: RegenXBio (RGNX), Climb Bio (CLYM)

TIPRANKS
·
Jun 06

REGENXBIO Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 06

Regenxbio price target lowered to $26 from $30 at H.C. Wainwright

TIPRANKS
·
Jun 06

Regenxbio Inc. : H.c. Wainwright Cuts Target Price to $26 From $30

THOMSON REUTERS
·
Jun 06

Regenxbio shareholders approved non-executive stock option exchange program at annual meeting

Reuters
·
Jun 03

Stifel Nicolaus Sticks to Their Buy Rating for RegenXBio (RGNX)

TIPRANKS
·
May 27

Nippon Shinyaku posts FY2025 earnings call transcript

Reuters
·
May 25

Regenxbio joins RBC Global Healthcare Conference fireside chat

Reuters
·
May 19